Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant female aged ≥ 18 years old.~2. Subject is pregnant for at least 3 months, inclusive.~3. Subject is willing and able to adhere to visit schedules and all study requirements.~4. Subject has read and signed the study-specific informed consent.~Exclusion Criteria:~1. Subject with previous complicated pregnancy or preterm delivery, spontaneous or medical abortion;~2. Subject with history or concurrent high risk of dangerous gestation such as gestational diabetes mellitus (GDM), pregnant induced hypertension, or preeclampsia;~3. Subject received any influenza vaccine within the previous 6 months;~4. Subject has a history of hypersensitivity to eggs or egg protein or similar pharmacological effects to study vaccine;~5. Subject or her family has the history of Guillain-Barré Syndrome;~6. Subject has current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours;~7. Subject with influenza-like illness as defined by the presence of fever (temperature over 38ºC) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;~8. Subject receive any treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent;~9. Subject has immunodeficiency or is under immunosuppressive treatment.~10. Subject received any vaccine within 1 week prior to study vaccination or expected to receive one within 1 week after study vaccination;~11. Subject received any blood products, including immunoglobulin, in the past 3 months before consent;~12. Subject has underlying condition in the investigators' opinion may interfere with evaluation of the vaccine;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).